Hansa Biopharma Enrolls First Patient In U.S. Randomized, Controlled Pivotal Trial Of Imlifidase In…
Hansa expects to complete enrollment in the second half of 2022 with a 12-month follow up completed in the second half of 2023
The U.S. randomized,…